Member Info for fundraiser222

The market opportunity in breast cancer for SFX-01 is $4.1bn in USA and Europe

Organization and published medical literature estimate that ca.85,000 individuals worldwide suffer an aneurysm SAH each year, with 30,000 to 35,000 being in the US and around 51,000 in Europe. All of these patients would potentially benefit from SFX-01. Based on an estimated price of $20,000 per course of treatment, this would equate to a market opportunity of $1.7b in just USA and Europe alone

The receipt of orphan drug designation in SAH is highly significant for Evgen Pharma and for our clinical programme in SAH, a devastating condition with high unmet clinical need. Evgen's SFX-01, has the potential to represent the first step-change improvement in the treatment of SAH in more than 20 years in that it targets the principal drivers of the delayed vasospasm.

The rest is owned by world class pharma investment funds, tells its own story if you lse ok at the share register and broker target is 97p, Evg is so far off the radar atm but not for much longer, I get the feeling the interim results due in next few weeks will contain a very positive update and the. We then look forward to the interim breast cancer data analysis due in q1 which if positive will push the price towards the broker target imo hugely undervalued at this all time low

To be had buying in at these levels and any placing mid way through next year and after the breast cancer interim data analysis will most likely be snapped up by our institutional investors such as axa who were more than happy to pay 37p 2 years ago and since then Evgen have made huge progress such as orphan drug designation, patents in USA and Europe, compassionate use program for the breast cancer trial due to no disease progression after 6 months! If imm can hit £130m mcap with a drug that can only be used for lupus Evgen can easily hit £200m mcap you only have to read the hard man report to understand the multi billion revenue potential of this company

And we are now coming to the business end of the trials witha full update due in next few weeks yet the share price is now at all time lows due to the tiny free float any sells drop it. But by the same token any decent buying and this will be back at the ipo price of 37p in the blink of any eye and if results are positive we can expect 100-200p very quickly

On the share register with Evgen and I am sure they will be more than happy to support the company further just like they did at 37p 2 years ago. Since then Evgen have grown and released nothing but positive news yet the share price has drifted due to impatience. With all the value and Trial readouts due during the next few months and in 2018 the share price will sail past 37p Ipo price and if the results are positive we could easily be looking at a 10 bagger just on the breast cancer trial alone. This really is a fantastic opportunity to accumulate before a transformational 2018 with a full update due in the next few weeks with the half yearly report

We should get a comprehensive update next month with the interim results which if positive will give the share price a good boost back into the 20p zone minimum. The multi billion dollar revenue potential has been completely missed by the market so far but I fully expect the interim results due in the next few weeks to wake the market up a bit as we also have the breast cancer trial interim data results to look forward to in q1 2018 so quite a few near term value catalysts in the next few months, 2018 will be a huge year here and I fully expect this to repeat the imm share price towards 100p as results draw closer

CEO stated in his June presentation that more funds would be required to complete the trials, as results are still a year away I just hope they can raise some extra money and the dilution isn’t destructive as they will be desperate for funds. Hopefully a placing around 12p in next few weeks rather than Darwin type funding but either way us shareholders are going to be in for a torrid time as we run out of cash in next few months

Few quid to be made here today

Taken a large position in sos today and looks like I am not the only one, fantastic driven bod with blue sky potential for worldwide expansion especially into the USA and China, will be a biggy I feel

More than a rush of blood to the head! Anr has just been valued at 0.05p that's all investors would pay to keep the lights on fact. If they lose the court case they will need another placing greater than the current one, this guy will flip these shares asap imo and if the court case is lost what will the next placing price be 0.02p... very sad for all holders here but the new buyers may want to look away at the end of today, losses will imo be huge

The new shareholders are now sitting on a 200% gain from their 0.05p buy in, I honestly worry for any pi who thinks buying a share when it has just had a 75% discount placing is a profitable idea lol, this will be below 0.10p very soon for sure imo after that placing and the claim pending

You would have to certified insane surley to buy a share that has just had a placing at a 75% discount to keep the lights on, and also has a court case claim that they are fighting that is greater than the total amount raised in the placing, like you say ART they valued ANR at no more than 0.05p says it all really even sino aus or wintask didn't want to buy any at 0.05p staggeringly bad price that placing

What tools are buying when a placing for 00.5p has just been announced lol, they can sell at 0.10p for 100% gain, insanity buying above 0.06p

Wow 75% discount lol disgraceful

Oh you heard the opppsite did you.... was that your friends in the city? Lol very embarrassing when ppl say they have heard a rumour, if good news was coming they would have no probs getting finance but as it states in the rns they are struggling to get finance

Here now unfortunately after all these years of failure, price is now so low any placing will likely be below 0.1p and it speaks volumes that wintask or sino aus don't want to take part in any placing and fund the company anymore..... looks game over

Yes it's A good tip for late 2018 but pointless buying now and waiting over a year for any results and buying on a spike, savy investors will be buying after the placing and below 15p, the last issue of equity of shares at 5p and 0.875p will also likely be selling this down for the rest of the week the mms seemed desperate to spike this today on very small volume and size of buys are beer money traders

Always stuns me at the amount of novice investors who buy the day after a newspaper mentions a share, the mms know it has been tipped so they shift the price up as high as possible praying ppl will still buy. Tiny volume today and all small buys so the mms did a great job of spiking it. Full read out of the phrase 2 trials has been delayed until the end of 2018 and they only have enough cash to last until early 2018.... can see this slipping back down to 15p during the rest of the week after today's spike, I intend on adding a few mid 2018 after any placing, pointless buying now with results more than a year away it will just fall back like usual below 15p imo